CYTOKINETICS, INCORPORATED (CYTK) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 139.02M; Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 139.02M | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 139.02M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2026-06-30 | 139.02M | (m) | (m) |
| 2026-03-31 | 124.43M | (m) | (m) |
| 2025-09-30 | 122.26M | (m) | (m) |
| 2025-06-30 | 119.66M | (m) | (m) |
| 2025-03-31 | 119.43M | (m) | (m) |
| 2024-09-30 | 118.01M | (m) | (m) |
| 2024-06-30 | 117.66M | (m) | (m) |
| 2024-03-31 | 104.85M | (m) | (m) |
| 2023-09-30 | 98.05M | (m) | (m) |
| 2023-06-30 | 96.00M | (m) | (m) |
| 2023-03-31 | 95.64M | (m) | (m) |
| 2022-12-31 | 95.16M | (m) | (m) |
| 2022-09-30 | 94.63M | (m) | (m) |
| 2022-06-30 | 94.14M | (m) | (m) |
| 2022-03-31 | 85.65M | (m) | (m) |
| 2021-09-30 | 83.88M | (m) | (m) |
| 2021-06-30 | 83.51M | (m) | (m) |
| 2021-03-31 | 71.74M | (m) | (m) |
| 2020-09-30 | 70.78M | (m) | (m) |
| 2020-06-30 | 70.50M | (m) | (m) |
| 2020-03-31 | 59.47M | (m) | (m) |
| 2019-12-31 | 59.45M | (m) | (m) |
| 2019-09-30 | 59.08M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |